Search Results

Bioequivalence of Reference and Biosimilar Preparations of Premixed Biphasic Insulin Aspart: A Comparative Clamp Study.

• Authors : Dorotenko A; R&D Center, GEROPHARM, Saint-Petersburg, Russia.; Makarenko I

Subjects: Biphasic Insulins* ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/adverse effects; Male

• Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Dec; Vol. 12 (12), pp. 1178-1184. Date of Electronic Publication: 2023 Sep 20.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Multiple drugs: Various toxicities : 40 case reports.

Subjects: *INSULIN antibodies; *BIPHASIC insulin; *CORONARY artery bypass

• Source: Reactions Weekly. Oct2024, Vol. 2028 Issue 1, p382-384. 3p.

Record details

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes.

• Authors : Luo Q; West China School of Pharmacy, Sichuan University, Chengdu, China.; Zhou L

Subjects: Biphasic Insulins*/Biphasic Insulins*/Biphasic Insulins*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy; Humans

• Source: Frontiers in public health [Front Public Health] 2022 Oct 18; Vol. 10, pp. 1016937. Date of Electronic Publication: 2022 Oct 18 (Print Publication: 2022).Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet

Record details

Elevated alanine aminotransferase is associated with biphasic insulin secretion in the healthy elderly Han Chinese population.

• Authors : Wu TY; Department of Internal Medicine, National Taiwan University Hospital, Taipei.; Liao EC

Subjects: Biphasic Insulins* ; Diabetes Mellitus, Type 2*; Aged

• Source: The Journal of international medical research [J Int Med Res] 2022 Sep; Vol. 50 (9), pp. 3000605221115161.Publisher: Sage Publications Country of Publication: England NLM ID: 0346411 Publication Model: Print Cited Medium: Internet ISSN: 1473-2300

Record details

Safety and effectiveness of a biosimilar biphasic insulin in the management of diabetes mellitus during routine clinical practice in Asian patients.

• Authors : Hussein Z; Hospital Putrajaya, 62000 Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia. .; Aziz NA

Subjects: Biosimilar Pharmaceuticals* ; Patient Safety*; Biphasic Insulins/Biphasic Insulins/Biphasic Insulins/*adverse effects

• Source: The Medical journal of Malaysia [Med J Malaysia] 2020 Jul; Vol. 75 (4), pp. 372-378.Publisher: Malaysian Medical Association Country of Publication: Malaysia NLM ID: 0361547 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.

• Authors : Yang W; China-Japan Friendship Hospital, Beijing, China.; Ma J

Subjects: Biphasic Insulins*/Biphasic Insulins*/Biphasic Insulins*/adverse effects ; Biphasic Insulins*/Biphasic Insulins*/Biphasic Insulins*/therapeutic use ; Hypoglycemic Agents*/Hypoglycemic Agents*/Hypoglycemic Agents*/adverse effects

• Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Jul; Vol. 21 (7), pp. 1652-1660. Date of Electronic Publication: 2019 Apr 04.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal–bolus insulin in UK clinical practice.

• Authors : Davies, Melanie J.^1,2 (AUTHOR) ; Alibegovic, Amra Ciric³ (AUTHOR); Kelkar, Pranav³ (AUTHOR)

Subjects: *INSULIN aspart; *BIPHASIC insulin; *GLYCEMIC controlUNITED KingdomNOVO Nordisk A/S NOVO Nordisk A/S NOVO Nordisk A/S NVO

• Source: Diabetes, Obesity & Metabolism. Dec2023, Vol. 25 Issue 12, p3841-3844. 4p.

Record details

Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs.

• Authors : Yang W; China-Japan Friendship Hospital, East Yinghuayuan Street, Hepingli, Beijing 100029, China. Electronic address: .; Ersoy C

Subjects: Biphasic Insulins/Biphasic Insulins/Biphasic Insulins/*therapeutic use ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemia/Hypoglycemia/Hypoglycemia/*prevention & control

• Source: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2019 Apr; Vol. 150, pp. 158-166. Date of Electronic Publication: 2019 Mar 11.Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet

Record details

A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.

• Authors : Guo L; Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Beijing, China.; Chen L

Subjects: Biphasic Insulins/Biphasic Insulins/Biphasic Insulins/*administration & dosage ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*administration & dosage

• Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Dec; Vol. 20 (12), pp. 2740-2747. Date of Electronic Publication: 2018 Aug 02.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.

• Authors : Liebl A; Department for Internal Medicine, Center for Diabetes and Metabolism, m&i-Fachklinik Bad Heilbrunn, Woernerweg 30, 83670, Bad Heilbrunn, Germany. .; Mohan V

Subjects: Biphasic Insulins/Biphasic Insulins/Biphasic Insulins/*therapeutic use ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Insulin Aspart/Insulin Aspart/Insulin Aspart/*therapeutic use

• Source: Drugs in R&D [Drugs R D] 2018 Mar; Vol. 18 (1), pp. 27-39.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100883647 Publication Model: Print Cited Medium: Internet ISSN:

Record details